Sign up to save your podcasts
Or
Share Recent Approvals From the FDA
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Recent Approvals From the FDA
The FDA certainly had a busy December, and this week, we'll be reviewing some recent approvals: olaparib for germline BRCA-mutated metastatic pancreatic cancer; fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive breast cancer; enfortumab vedotin-ejfv for previously treated advanced urothelial cancer; enzalutamide for metastatic castration-sensitive prostate cancer; and atezolizumab in combination with chemotherapy for the first-line treatment of adults with metastatic nonsquamous non–small cell lung cancer.
Coverage of stories discussed this week on ascopost.com:
FDA Approves Olaparib for Patients With Germline BRCA-Mutated Metastatic Pancreatic Cancer
FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Patients With Unresectable or Metastatic HER2-Positive Breast Cancer
FDA Approves Enfortumab Vedotin-ejfv for Previously Treated Advanced Urothelial Cancer
FDA Approves Enzalutamide for Patients With Metastatic Castration-Sensitive Prostate Cancer
FDA Approves PD-L1 Inhibitor Plus Chemotherapy for First-Line Treatment of Metastatic Nonsquamous Non–Small Cell Lung Cancer
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> The FDA certainly had a busy December, and this week, we'll be reviewing some recent approvals: olaparib for germline BRCA-mutated metastatic pancreatic cancer; fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive breast cancer; enfortumab vedotin-ejfv for previously treated advanced urothelial cancer; enzalutamide for metastatic castration-sensitive prostate cancer; and atezolizumab in combination with chemotherapy for the first-line treatment of adults with metastatic nonsquamous non–small cell lung cancer.The FDA certainly had a busy December, and this week, we'll be reviewing some recent approvals: olaparib for germline BRCA-mutated metastatic pancreatic cancer; fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive breast cancer; enfortumab vedotin-ejfv for previously treated advanced urothelial cancer; enzalutamide for metastatic castration-sensitive prostate cancer; and atezolizumab in combination with chemotherapy for the first-line treatment of adults with metastatic nonsquamous non–small cell lung cancer.
Coverage of stories discussed this week on ascopost.com:
FDA Approves Olaparib for Patients With Germline BRCA-Mutated Metastatic Pancreatic Cancer
FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Patients With Unresectable or Metastatic HER2-Positive Breast Cancer
FDA Approves Enfortumab Vedotin-ejfv for Previously Treated Advanced Urothelial Cancer
FDA Approves Enzalutamide for Patients With Metastatic Castration-Sensitive Prostate Cancer
FDA Approves PD-L1 Inhibitor Plus Chemotherapy for First-Line Treatment of Metastatic Nonsquamous Non–Small Cell Lung Cancer
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Coverage of stories discussed this week on ascopost.com:The FDA certainly had a busy December, and this week, we'll be reviewing some recent approvals: olaparib for germline BRCA-mutated metastatic pancreatic cancer; fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive breast cancer; enfortumab vedotin-ejfv for previously treated advanced urothelial cancer; enzalutamide for metastatic castration-sensitive prostate cancer; and atezolizumab in combination with chemotherapy for the first-line treatment of adults with metastatic nonsquamous non–small cell lung cancer.
Coverage of stories discussed this week on ascopost.com:
FDA Approves Olaparib for Patients With Germline BRCA-Mutated Metastatic Pancreatic Cancer
FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Patients With Unresectable or Metastatic HER2-Positive Breast Cancer
FDA Approves Enfortumab Vedotin-ejfv for Previously Treated Advanced Urothelial Cancer
FDA Approves Enzalutamide for Patients With Metastatic Castration-Sensitive Prostate Cancer
FDA Approves PD-L1 Inhibitor Plus Chemotherapy for First-Line Treatment of Metastatic Nonsquamous Non–Small Cell Lung Cancer
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> FDA Approves Olaparib for Patients With Germline BRCA The FDA certainly had a busy December, and this week, we'll be reviewing some recent approvals: olaparib for germline BRCA-mutated metastatic pancreatic cancer; fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive breast cancer; enfortumab vedotin-ejfv for previously treated advanced urothelial cancer; enzalutamide for metastatic castration-sensitive prostate cancer; and atezolizumab in combination with chemotherapy for the first-line treatment of adults with metastatic nonsquamous non–small cell lung cancer.Coverage of stories discussed this week on ascopost.com:
FDA Approves Olaparib for Patients With Germline BRCA-Mutated Metastatic Pancreatic Cancer
FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Patients With Unresectable or Metastatic HER2-Positive Breast Cancer
FDA Approves Enfortumab Vedotin-ejfv for Previously Treated Advanced Urothelial Cancer
FDA Approves Enzalutamide for Patients With Metastatic Castration-Sensitive Prostate Cancer
FDA Approves PD-L1 Inhibitor Plus Chemotherapy for First-Line Treatment of Metastatic Nonsquamous Non–Small Cell Lung Cancer
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Mutated Metastatic Pancreatic CancerThe FDA certainly had a busy December, and this week, we'll be reviewing some recent approvals: olaparib for germline BRCA-mutated metastatic pancreatic cancer; fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive breast cancer; enfortumab vedotin-ejfv for previously treated advanced urothelial cancer; enzalutamide for metastatic castration-sensitive prostate cancer; and atezolizumab in combination with chemotherapy for the first-line treatment of adults with metastatic nonsquamous non–small cell lung cancer.
Coverage of stories discussed this week on ascopost.com:
FDA Approves Olaparib for Patients With Germline BRCA-Mutated Metastatic Pancreatic Cancer
FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Patients With Unresectable or Metastatic HER2-Positive Breast Cancer
FDA Approves Enfortumab Vedotin-ejfv for Previously Treated Advanced Urothelial Cancer
FDA Approves Enzalutamide for Patients With Metastatic Castration-Sensitive Prostate Cancer
FDA Approves PD-L1 Inhibitor Plus Chemotherapy for First-Line Treatment of Metastatic Nonsquamous Non–Small Cell Lung Cancer
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Patients With Unresectable or Metastatic HER2-Positive Breast CancerThe FDA certainly had a busy December, and this week, we'll be reviewing some recent approvals: olaparib for germline BRCA-mutated metastatic pancreatic cancer; fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive breast cancer; enfortumab vedotin-ejfv for previously treated advanced urothelial cancer; enzalutamide for metastatic castration-sensitive prostate cancer; and atezolizumab in combination with chemotherapy for the first-line treatment of adults with metastatic nonsquamous non–small cell lung cancer.
Coverage of stories discussed this week on ascopost.com:
FDA Approves Olaparib for Patients With Germline BRCA-Mutated Metastatic Pancreatic Cancer
FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Patients With Unresectable or Metastatic HER2-Positive Breast Cancer
FDA Approves Enfortumab Vedotin-ejfv for Previously Treated Advanced Urothelial Cancer
FDA Approves Enzalutamide for Patients With Metastatic Castration-Sensitive Prostate Cancer
FDA Approves PD-L1 Inhibitor Plus Chemotherapy for First-Line Treatment of Metastatic Nonsquamous Non–Small Cell Lung Cancer
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> FDA Approves Enfortumab Vedotin-ejfv for Previously Treated Advanced Urothelial CancerThe FDA certainly had a busy December, and this week, we'll be reviewing some recent approvals: olaparib for germline BRCA-mutated metastatic pancreatic cancer; fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive breast cancer; enfortumab vedotin-ejfv for previously treated advanced urothelial cancer; enzalutamide for metastatic castration-sensitive prostate cancer; and atezolizumab in combination with chemotherapy for the first-line treatment of adults with metastatic nonsquamous non–small cell lung cancer.
Coverage of stories discussed this week on ascopost.com:
FDA Approves Olaparib for Patients With Germline BRCA-Mutated Metastatic Pancreatic Cancer
FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Patients With Unresectable or Metastatic HER2-Positive Breast Cancer
FDA Approves Enfortumab Vedotin-ejfv for Previously Treated Advanced Urothelial Cancer
FDA Approves Enzalutamide for Patients With Metastatic Castration-Sensitive Prostate Cancer
FDA Approves PD-L1 Inhibitor Plus Chemotherapy for First-Line Treatment of Metastatic Nonsquamous Non–Small Cell Lung Cancer
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> FDA Approves Enzalutamide for Patients With Metastatic Castration-Sensitive Prostate CancerThe FDA certainly had a busy December, and this week, we'll be reviewing some recent approvals: olaparib for germline BRCA-mutated metastatic pancreatic cancer; fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive breast cancer; enfortumab vedotin-ejfv for previously treated advanced urothelial cancer; enzalutamide for metastatic castration-sensitive prostate cancer; and atezolizumab in combination with chemotherapy for the first-line treatment of adults with metastatic nonsquamous non–small cell lung cancer.
Coverage of stories discussed this week on ascopost.com:
FDA Approves Olaparib for Patients With Germline BRCA-Mutated Metastatic Pancreatic Cancer
FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Patients With Unresectable or Metastatic HER2-Positive Breast Cancer
FDA Approves Enfortumab Vedotin-ejfv for Previously Treated Advanced Urothelial Cancer
FDA Approves Enzalutamide for Patients With Metastatic Castration-Sensitive Prostate Cancer
FDA Approves PD-L1 Inhibitor Plus Chemotherapy for First-Line Treatment of Metastatic Nonsquamous Non–Small Cell Lung Cancer
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> FDA Approves PD-L1 Inhibitor Plus Chemotherapy for First-Line Treatment of Metastatic Nonsquamous Non–Small Cell Lung Cancer
View all episodes
By BroadcastMed
4.5
1515 ratings
The FDA certainly had a busy December, and this week, we'll be reviewing some recent approvals: olaparib for germline BRCA-mutated metastatic pancreatic cancer; fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive breast cancer; enfortumab vedotin-ejfv for previously treated advanced urothelial cancer; enzalutamide for metastatic castration-sensitive prostate cancer; and atezolizumab in combination with chemotherapy for the first-line treatment of adults with metastatic nonsquamous non–small cell lung cancer.
Coverage of stories discussed this week on ascopost.com:
FDA Approves Olaparib for Patients With Germline BRCA-Mutated Metastatic Pancreatic Cancer
FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Patients With Unresectable or Metastatic HER2-Positive Breast Cancer
FDA Approves Enfortumab Vedotin-ejfv for Previously Treated Advanced Urothelial Cancer
FDA Approves Enzalutamide for Patients With Metastatic Castration-Sensitive Prostate Cancer
FDA Approves PD-L1 Inhibitor Plus Chemotherapy for First-Line Treatment of Metastatic Nonsquamous Non–Small Cell Lung Cancer
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> The FDA certainly had a busy December, and this week, we'll be reviewing some recent approvals: olaparib for germline BRCA-mutated metastatic pancreatic cancer; fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive breast cancer; enfortumab vedotin-ejfv for previously treated advanced urothelial cancer; enzalutamide for metastatic castration-sensitive prostate cancer; and atezolizumab in combination with chemotherapy for the first-line treatment of adults with metastatic nonsquamous non–small cell lung cancer.The FDA certainly had a busy December, and this week, we'll be reviewing some recent approvals: olaparib for germline BRCA-mutated metastatic pancreatic cancer; fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive breast cancer; enfortumab vedotin-ejfv for previously treated advanced urothelial cancer; enzalutamide for metastatic castration-sensitive prostate cancer; and atezolizumab in combination with chemotherapy for the first-line treatment of adults with metastatic nonsquamous non–small cell lung cancer.
Coverage of stories discussed this week on ascopost.com:
FDA Approves Olaparib for Patients With Germline BRCA-Mutated Metastatic Pancreatic Cancer
FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Patients With Unresectable or Metastatic HER2-Positive Breast Cancer
FDA Approves Enfortumab Vedotin-ejfv for Previously Treated Advanced Urothelial Cancer
FDA Approves Enzalutamide for Patients With Metastatic Castration-Sensitive Prostate Cancer
FDA Approves PD-L1 Inhibitor Plus Chemotherapy for First-Line Treatment of Metastatic Nonsquamous Non–Small Cell Lung Cancer
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Coverage of stories discussed this week on ascopost.com:The FDA certainly had a busy December, and this week, we'll be reviewing some recent approvals: olaparib for germline BRCA-mutated metastatic pancreatic cancer; fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive breast cancer; enfortumab vedotin-ejfv for previously treated advanced urothelial cancer; enzalutamide for metastatic castration-sensitive prostate cancer; and atezolizumab in combination with chemotherapy for the first-line treatment of adults with metastatic nonsquamous non–small cell lung cancer.
Coverage of stories discussed this week on ascopost.com:
FDA Approves Olaparib for Patients With Germline BRCA-Mutated Metastatic Pancreatic Cancer
FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Patients With Unresectable or Metastatic HER2-Positive Breast Cancer
FDA Approves Enfortumab Vedotin-ejfv for Previously Treated Advanced Urothelial Cancer
FDA Approves Enzalutamide for Patients With Metastatic Castration-Sensitive Prostate Cancer
FDA Approves PD-L1 Inhibitor Plus Chemotherapy for First-Line Treatment of Metastatic Nonsquamous Non–Small Cell Lung Cancer
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> FDA Approves Olaparib for Patients With Germline BRCA The FDA certainly had a busy December, and this week, we'll be reviewing some recent approvals: olaparib for germline BRCA-mutated metastatic pancreatic cancer; fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive breast cancer; enfortumab vedotin-ejfv for previously treated advanced urothelial cancer; enzalutamide for metastatic castration-sensitive prostate cancer; and atezolizumab in combination with chemotherapy for the first-line treatment of adults with metastatic nonsquamous non–small cell lung cancer.Coverage of stories discussed this week on ascopost.com:
FDA Approves Olaparib for Patients With Germline BRCA-Mutated Metastatic Pancreatic Cancer
FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Patients With Unresectable or Metastatic HER2-Positive Breast Cancer
FDA Approves Enfortumab Vedotin-ejfv for Previously Treated Advanced Urothelial Cancer
FDA Approves Enzalutamide for Patients With Metastatic Castration-Sensitive Prostate Cancer
FDA Approves PD-L1 Inhibitor Plus Chemotherapy for First-Line Treatment of Metastatic Nonsquamous Non–Small Cell Lung Cancer
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Mutated Metastatic Pancreatic CancerThe FDA certainly had a busy December, and this week, we'll be reviewing some recent approvals: olaparib for germline BRCA-mutated metastatic pancreatic cancer; fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive breast cancer; enfortumab vedotin-ejfv for previously treated advanced urothelial cancer; enzalutamide for metastatic castration-sensitive prostate cancer; and atezolizumab in combination with chemotherapy for the first-line treatment of adults with metastatic nonsquamous non–small cell lung cancer.
Coverage of stories discussed this week on ascopost.com:
FDA Approves Olaparib for Patients With Germline BRCA-Mutated Metastatic Pancreatic Cancer
FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Patients With Unresectable or Metastatic HER2-Positive Breast Cancer
FDA Approves Enfortumab Vedotin-ejfv for Previously Treated Advanced Urothelial Cancer
FDA Approves Enzalutamide for Patients With Metastatic Castration-Sensitive Prostate Cancer
FDA Approves PD-L1 Inhibitor Plus Chemotherapy for First-Line Treatment of Metastatic Nonsquamous Non–Small Cell Lung Cancer
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Patients With Unresectable or Metastatic HER2-Positive Breast CancerThe FDA certainly had a busy December, and this week, we'll be reviewing some recent approvals: olaparib for germline BRCA-mutated metastatic pancreatic cancer; fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive breast cancer; enfortumab vedotin-ejfv for previously treated advanced urothelial cancer; enzalutamide for metastatic castration-sensitive prostate cancer; and atezolizumab in combination with chemotherapy for the first-line treatment of adults with metastatic nonsquamous non–small cell lung cancer.
Coverage of stories discussed this week on ascopost.com:
FDA Approves Olaparib for Patients With Germline BRCA-Mutated Metastatic Pancreatic Cancer
FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Patients With Unresectable or Metastatic HER2-Positive Breast Cancer
FDA Approves Enfortumab Vedotin-ejfv for Previously Treated Advanced Urothelial Cancer
FDA Approves Enzalutamide for Patients With Metastatic Castration-Sensitive Prostate Cancer
FDA Approves PD-L1 Inhibitor Plus Chemotherapy for First-Line Treatment of Metastatic Nonsquamous Non–Small Cell Lung Cancer
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> FDA Approves Enfortumab Vedotin-ejfv for Previously Treated Advanced Urothelial CancerThe FDA certainly had a busy December, and this week, we'll be reviewing some recent approvals: olaparib for germline BRCA-mutated metastatic pancreatic cancer; fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive breast cancer; enfortumab vedotin-ejfv for previously treated advanced urothelial cancer; enzalutamide for metastatic castration-sensitive prostate cancer; and atezolizumab in combination with chemotherapy for the first-line treatment of adults with metastatic nonsquamous non–small cell lung cancer.
Coverage of stories discussed this week on ascopost.com:
FDA Approves Olaparib for Patients With Germline BRCA-Mutated Metastatic Pancreatic Cancer
FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Patients With Unresectable or Metastatic HER2-Positive Breast Cancer
FDA Approves Enfortumab Vedotin-ejfv for Previously Treated Advanced Urothelial Cancer
FDA Approves Enzalutamide for Patients With Metastatic Castration-Sensitive Prostate Cancer
FDA Approves PD-L1 Inhibitor Plus Chemotherapy for First-Line Treatment of Metastatic Nonsquamous Non–Small Cell Lung Cancer
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> FDA Approves Enzalutamide for Patients With Metastatic Castration-Sensitive Prostate CancerThe FDA certainly had a busy December, and this week, we'll be reviewing some recent approvals: olaparib for germline BRCA-mutated metastatic pancreatic cancer; fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive breast cancer; enfortumab vedotin-ejfv for previously treated advanced urothelial cancer; enzalutamide for metastatic castration-sensitive prostate cancer; and atezolizumab in combination with chemotherapy for the first-line treatment of adults with metastatic nonsquamous non–small cell lung cancer.
Coverage of stories discussed this week on ascopost.com:
FDA Approves Olaparib for Patients With Germline BRCA-Mutated Metastatic Pancreatic Cancer
FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Patients With Unresectable or Metastatic HER2-Positive Breast Cancer
FDA Approves Enfortumab Vedotin-ejfv for Previously Treated Advanced Urothelial Cancer
FDA Approves Enzalutamide for Patients With Metastatic Castration-Sensitive Prostate Cancer
FDA Approves PD-L1 Inhibitor Plus Chemotherapy for First-Line Treatment of Metastatic Nonsquamous Non–Small Cell Lung Cancer
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> FDA Approves PD-L1 Inhibitor Plus Chemotherapy for First-Line Treatment of Metastatic Nonsquamous Non–Small Cell Lung Cancer